5-MeO-DMT & CBT in Alcohol Use Disorder: UK Trial Insights

Phase 2a Trial Reveals Psychological Shifts with 5-MeO-DMT and CBT

A recent phase 2a clinical trial conducted in London, UK, has provided new insights into the potential therapeutic benefits of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) when combined with cognitive behavioral therapy (CBT) for treating alcohol use disorder (AUD). The study, which ran from March 2023 to July 2024, involved ten participants with moderate to severe AUD and explored the psychological change processes facilitated by this combination therapy.

Mechanisms of Psychological Change in 5-MeO-DMT Therapy

The qualitative study embedded within the trial utilized semi-structured interviews to capture the experiences of participants and therapists. Participants described their dosing-day experiences with metaphors such as "reset," "cleansing," and "rebirth," indicating significant emotional catharsis and shifts in self-perception. These experiences were associated with increased clarity about their relationship with alcohol, heightened emotional openness, and improved self-compassion.

At the 12-week follow-up, participants who maintained abstinence reported the psychedelic experience as a pivotal turning point, facilitating sustained reappraisals of identity and alcohol use patterns. Those who resumed moderated drinking also noted increased self-awareness and emotional regulation. Therapist accounts corroborated these findings, highlighting shifts in psychological flexibility and adaptive behavioral responses.

Implications for Future Research and Policy

The findings from this trial suggest that 5-MeO-DMT, when integrated with CBT, could be a promising approach for supporting abstinence and improving well-being in individuals with AUD. This research adds to the growing evidence base for psychedelic-assisted therapies in addiction treatment, potentially informing future therapeutic approaches and policy decisions. The study's insights could guide the development of more targeted interventions that harness the psychological change processes facilitated by psychedelics.

Risks and Unknowns in Psychedelic-Assisted Therapy

While the trial's results are promising, several risks and unknowns remain. The study involved a small sample size, limiting the generalizability of the findings. Additionally, the long-term effects of 5-MeO-DMT use in combination with CBT are not yet fully understood, necessitating further research to assess safety and efficacy over extended periods. Potential adverse effects and the variability of individual responses to psychedelics also warrant careful consideration in future studies.

Looking Ahead: The Future of Psychedelic-Assisted Therapies

As interest in psychedelic-assisted therapies continues to grow, this study underscores the importance of rigorous clinical research to explore their potential benefits and limitations. Future trials should aim to include larger and more diverse participant groups to enhance the robustness of findings. Additionally, understanding the mechanisms underlying the psychological change processes observed in this trial could inform the development of more effective and personalized treatment protocols.